The stock's overall trend has been significantly negative over the past six months, with a decline of 21.33%. It has underperformed the broader market, as indicated by a relative strength of -18.51 over the same period. The price has fallen from over $122 in early October 2025 to the mid-$90s by the end of March 2026. Short-term performance shows continued weakness, with the stock down 13.43% over the past month. This decline is more severe than the S&P 500's 5.25% drop, resulting in negative relative strength of -8.18. Over the last three months, the stock is down 4.38%, slightly outperforming the market's 4.63% decline. The current price of $96.47 is near the bottom of its 52-week range of $94.54 to $147.12, representing a drawdown of approximately 34.4% from the high. The stock's beta of 0.234 indicates it has been significantly less volatile than the market during this downtrend.

Revenue and profitability have shown pressure. For Q4 2025, revenue was $4.08 billion, representing a year-over-year decline of 17.21%. The quarterly net margin was 12.23%, which is an improvement from the 9.07% margin in Q4 2024, but net income of $499 million was down from the prior year's Q1 high of $567 million. The trailing twelve-month free cash flow remains solid at $2.38 billion. Financial health is a concern due to a high degree of leverage. The debt-to-equity ratio is elevated at 4.77. However, the company maintains a current ratio of 0.75 and generated substantial operating cash flow of $972 million in the latest quarter, providing some coverage for its obligations. Operational efficiency metrics are mixed. Return on Equity (ROE) is exceptionally high at 134.55%, but this is largely a function of the high financial leverage (low equity base). Return on Assets (ROA) is a more modest 9.61%. The net margin for the latest quarter was a healthy 12.23%, supported by a gross margin of 35.91%.